TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30707210
Drug: Early protocolized
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early protocolized rehabilitation (consultation of physical therapy, occupational therapy, and speech and language therapy within 72 hours of ICU admission, n = 26)
Study: 26059899
Drug: D2 supplementation
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 supplementation (100 IU/kg daily)
Study: 26059899
Drug: D3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 supplementation (100 IU/kg daily)
Study: 26059899
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 IU/kg daily)
Study: 25317722
Drug: Oral application
Normalized name: Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral application of 5 mL CHX 0.12% solution before intubation
Study: 21828387
Drug: 3.5% menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5% menthol gel
Study: 19903643
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) followed by low-level diode laser treatment for 5 days (Group B)
Study: 19903643
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) followed by low-level diode laser treatment for 10 days (Group C)
Study: 9921711
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (aim: aPTT approximately 2 x normal)
Study: 1984373
Drug: Thiopental 6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 6.5 mg/kg
Study: 6412673
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of sodium cromoglycate (SCG) aerosol
Study: 6412673
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of sodium cromoglycate (SCG) aerosol
Study: 6412673
Drug: 2 or
Normalized name: CP-2 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 or 4 mg of sodium cromoglycate (SCG) aerosol
Study: 3894841
Drug: Betahistine dimesilate
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine dimesilate 36 mg daily for at least six weeks
Study: 27739262
Drug: Carica papaya
Normalized name: Carica papaya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carica papaya leaf extract (CPLE) administered three times daily for five days
Study: 20530518
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of dalteparin
Study: 20530518
Drug: Half-dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose of dalteparin
Study: 16169400
Drug: L-acetylcarnitine (LAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-acetylcarnitine (LAC) 3 g/d
Study: 16169400
Drug: Combined L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined L-carnitine (LC) 2 g/d and L-acetylcarnitine (LAC) 1 g/d
Study: 10655964
Drug: Retinyl palmitate
Normalized name: Retinyl palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl palmitate by inhalation (2 puffs of aerosol containing 1 mg per delivery, total 2 mg over 3 months)
Study: 1715478
Drug: nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrendipine 10 mg b.i.d. (n = 39)
Study: 1715478
Drug: nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrendipine 20 mg o.d. (n = 39)
Study: 1715478
Drug: nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrendipine 10 mg b.i.d. (n = 32)
Study: 1715478
Drug: nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrendipine 20 mg o.d. (n = 28)
Study: 1715478
Drug: nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrendipine 20 mg o.d.
Study: 1715478
Drug: nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrendipine 10 mg b.i.d.
Study: 6358177
Drug: Thienamycin formamidine/renal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thienamycin formamidine/renal dipeptidase inhibitor
Study: 30268384
Drug: iv administration
Normalized name: IV Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv administration of GLP-1 receptor antagonist exendin(9-39) + ischemia-reperfusion + RIC
Study: 12148881
Drug: Prophylactic doses
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic doses of nadroparin (Fraxiparine)
Study: 1104060
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin prophylaxis (Control)
Study: 1855751
Drug: Phytodolor N
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytodolor N (3 x 30 drops daily for 3 weeks)
Study: 27981528
Drug: 0.1 g
Normalized name: BIOTIN 0.1 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g Bayaspirin (ASA II group) administered at draught before sleep
Study: 27981528
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Adalat (control group) administered orally once a day
Study: 27981528
Drug: 0.1 g
Normalized name: BIOTIN 0.1 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g Bayaspirin (ASA I group) administered at draught in the morning
Study: 24571870
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.5% ropivacaine injected peri‐incisionally with pulmonary recruitment manoeuvre (Group 2)
Study: 24571870
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.5% ropivacaine injected peri‐incisionally without pulmonary recruitment manoeuvre (Group 1)
Study: 23259913
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (daily sessions)
Study: 23259913
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (for compliant women)
Study: 16109056
Drug: Eletriptan 40
Normalized name: eletriptan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eletriptan 40 mg (mild pain intensity)
Study: 11823892
Drug: Smoked cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cocaine (0, 6, 12, or 25 mg cocaine base, depending on the session) administered during the follicular phase.
Study: 11823892
Drug: Smoked cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cocaine (0, 6, 12, or 25 mg cocaine base, depending on the session) administered during the luteal phase.
Study: 10459958
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg tablets), one tablet twice daily until the onset of labour, one tablet at onset of labour, and one tablet every 3 h until delivery
Study: 10459958
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg tablets)
Study: 576887
Drug: 1,500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg/day of diethylstibestrol (DES)
Study: 576887
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day of diethylstibestrol (DES)
Study: 576887
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day of diethylstibestrol (DES)
Study: 576887
Drug: 1.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/day of diethylstibestrol (DES)
Study: 28333536
Drug: Mom-Net intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mom-Net intervention (8-session, Internet-facilitated cognitive-behavioral treatment)
Study: 23160726
Drug: Imeglimin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imeglimin (1,500 mg twice a day)
Study: 23160726
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to metformin (1,500-2,000 mg/day)
Study: 21777737
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with CERTIFECT (fipronil, amitraz, and (S)-methoprene) applied 28 days prior to tick infestation
Study: 21777737
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with CERTIFECT applied 21 days prior to tick infestation
Study: 21777737
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with CERTIFECT applied 14 days prior to tick infestation
Study: 21777737
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with CERTIFECT applied 7 days prior to tick infestation
Study: 20635778
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for psychosis, focusing on education about symptoms and cognitive models, including collaborative exploration of thoughts and schemas surrounding delusions and hallucinations.
Study: 10461765
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg)
Study: 30946207
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 mg every 2 weeks; increased to 150 mg at Week 12 if LDL-C ≥ 70 mg/dL at Week 8)
Study: 23330822
Drug: topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical diclofenac + tobramycin
Study: 23330822
Drug: topical tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: topical tobramycin
Study: 23330822
Drug: topical naphazoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical naphazoline
Study: 15017615
Drug: Lumiracoxib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib (800 mg every day)
Study: 9230275
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of 0.7 mg free folic acid in cereal for 2 months followed by 2.0 mg free folic acid via a tablet for 4 months
Study: 9230275
Drug: Normal folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal folate and vitamin B12, but homocysteine levels >10 micromol/l
Study: 8197064
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy program for behaviorally disordered mentally handicapped patients
Study: 29433545
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation treatment using the GRADIOR programme
Study: 29433545
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment consisting of GRADIOR and ehcoBUTLER
Study: 27756783
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of 7 lipid species to a base model (14 traditional risk factors and medications)
Study: 24831037
Drug: Automated telecommunication-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated telecommunication-based reminders (daily messages via text or voice)
Study: 22935508
Drug: Oral ulcers
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral ulcers
Study: 22935508
Drug: 10 or
Normalized name: K-10 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 or more oral ulcers during 6 months
Study: 18174609
Drug: High-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose regimen (HD): two cycles of E(90)C(600) every 2 weeks followed by two cycles of E(90)C(3000)Thiotepa(400) every 3 weeks.
Study: 18174609
Drug: Dose-dense conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense conventional chemotherapy (DD): four cycles of E(90)C(600) followed by three cycles of C(600)M(40)F(600) every 2 weeks.
Study: 8839500
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet with 10 mg total carotenoids/d for two cycles
Study: 8098281
Drug: Ibopamine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (3 x 100 mg/day p.o.)
Study: 2441736
Drug: PVB chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVB chemotherapy (cisplatin, vinblastine, and bleomycin)
Study: 29940166
Drug: rAAV2.REP1 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV2.REP1 (0.1 mL containing 10^11 genome particles)
Study: 31623894
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h)
Study: 15730542
Drug: DVP delayed-release/sprinkle
Approvals — FDA: no, EMA: no, PMDA: no
Description: DVP delayed-release/sprinkle
Study: 15730542
Drug: DVP sprinkle
Approvals — FDA: no, EMA: no, PMDA: no
Description: DVP sprinkle formulation
Study: 15730542
Drug: DVP extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: DVP extended-release tablets
Study: 11085961
Drug: Trained (TR)
Normalized name: hyoscyamine sulfate Extended Release Oral Tablet [Hyoscyamine TR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trained (TR) group underwent a residential exercise program at 85% of maximum heart rate, consisting of 2 daily sessions 6 times a week for 2 weeks.
Study: 3926322
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (275 mg each, 3 tablets)
Study: 3926322
Drug: Ergotamine combination
Normalized name: ergotamine, combinations excl. psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergotamine combination (2 mg ergotamine tartrate, 91.5 mg caffeine, 50 mg cyclizine chlorhydrate, 1 tablet)
Study: 3926322
Drug: Ergotamine combination
Normalized name: ergotamine, combinations excl. psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergotamine combination
Study: 31079072
Drug: Metformin (n=45)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (n=45)
Study: 29859789
Drug: Hypofractionated whole-breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated whole-breast radiation therapy (RT)
Study: 574352
Drug: Soy isolate-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isolate-based formula supplemented with L-methionine
Study: 19307271
Drug: Repeat prenatal
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat prenatal corticosteroid treatment (weekly betamethasone)
Study: 15053915
Drug: Panavia Fluoro
Normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Panavia Fluoro Cement with AD gel (AD/Panavia); bonded with 4‐META/MMA‐TBB resin.
Study: 9725481
Drug: Manidipine 20
Normalized name: manidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 20 mg tablet administered after a standardized breakfast
Study: 7848346
Drug: Vita‐Gerin‐Geistlich (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vita‐Gerin‐Geistlich (1 capsule/day)
Study: 3178294
Drug: Oral breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral breathing during 30-min exposure to approximately 0.4 ppm O3
Study: 167583
Drug: Neomycin and
Normalized name: Neomycin and polymyxin B only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin and Polymyxin B combination
Study: 31289351
Drug: Adjuvant fluorouracil-based
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant fluorouracil-based chemotherapy
Study: 28296257
Drug: Rituximab (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1,000 mg in 250 ml saline) administered in 2 courses at weeks 0, 2, 24, and 26.
Study: 28296257
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 ml saline) administered in 2 courses at weeks 0, 2, 24, and 26.
Study: 21631494
Drug: Sublingual feverfew/ginger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual feverfew/ginger
Study: 17595032
Drug: Autologous Preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Preparation Rich in Growth Factors (PRGF)
Study: 12956892
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin (40 mg/kg/day in 3 divided doses) for 5 days
Study: 12956892
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin (40 mg/kg/day in 3 divided doses) for 10 days
Study: 12956892
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin (40 mg/kg/day in 3 divided doses) for 15 days
Study: 10855738
Drug: Trandolapril/verapamil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril/verapamil (2 mg/180 mg)
Study: 9115527
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus a 15‐minute tepid sponge bath
Study: 1288925
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxibustion (warming needle and point injection)
Study: 2871418
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (200,000 IU capsules distributed twice, 1-3 months and 6 months after baseline)
Study: 24373754
Drug: 3% sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% sevoflurane for 3 min via face mask with tidal volume of 2.2 ml kg(‐1) (Group 1)
Study: 24373754
Drug: 3% sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% sevoflurane for 3 min via face mask with tidal volume of 8 ml kg(‐1) (Group 2)
Study: 24373754
Drug: 3% sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% sevoflurane for 3 min via face mask with tidal volume of 12 ml kg(‐1) (Group 3)
Study: 22839514
Drug: Quinapril 21.0±5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 21.0±5 mg/day
Study: 22839514
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate 87.7±7.6 mg/day
Study: 19165592
Drug: Family-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused cognitive behavioral therapy (FCBT)
Study: 18254226
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate therapy for 12 months
Study: 18254226
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate therapy
Study: 8588791
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose hyoscine
Study: 8588791
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose hyoscine and pyridostigmine
Study: 16410483
Drug: Aspirin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (160 mg per day)
Study: 30829892
Drug: High-fidelity training
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fidelity training model for dynamic ONSD measurement using ETT cuff volumes of 0.1 mL, 0.2 mL, and 0.3 mL.
Study: 14674932
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg oral, bedtime)
Study: 8490637
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cognitive-behavioral treatment and desipramine
Study: 3829579
Drug: Meptazinol 140
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 140 mg
Study: 3829579
Drug: Meptazinol 280
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 280 mg
Study: 3829579
Drug: Meptazinol (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (therapeutic dose range)
Study: 27502703
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose of 59.4-60 Gy
Study: 27502703
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose of 61-69 Gy
Study: 27502703
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose of ≥70 Gy
Study: 27502703
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose of 66 Gy
Study: 27502703
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose of 70 Gy
Study: 27502703
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose of ≥71 Gy
Study: 12436219
Drug: Standard twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard twice a week G-CSF prophylaxis
Study: 9579238
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms oral desmopressin without a meal (Day B)
Study: 9579238
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms oral desmopressin with a standard meal (Day C)
Study: 9579238
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms oral desmopressin 1.5 hours after a standard meal (Day D)
Study: 9579238
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatment days (B, C, D)
Study: 7699968
Drug: Methylprednisolone 20
Normalized name: methylprednisolone 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 20 mg per day for three days
Study: 27988297
Drug: Inhaled glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glutathione (GSH) treatment for 6 months